- Home
- LEU vs EYPT Comparison
LEU vs EYPT Comparison
Compare LEU & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEU | EYPT |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 1.5B |
| IPO Year | 1998 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LEU | EYPT |
|---|---|---|
| Price | $209.67 | $12.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $238.83 | $31.80 |
| AVG Volume (30 Days) | 792.2K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.90 | N/A |
| Revenue | ★ $193,000,000.00 | $7,539,000.00 |
| Revenue This Year | $4.56 | N/A |
| Revenue Next Year | $6.07 | $965.51 |
| P/E Ratio | $55.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.77 | $3.91 |
| 52 Week High | $464.00 | $19.11 |
Technical Indicators
Market Signals| Indicator | LEU | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 35.42 |
| Support Level | $188.20 | $11.88 |
| Resistance Level | $216.09 | $14.24 |
| Average True Range (ATR) | 14.25 | 1.16 |
| MACD | 3.94 | -0.43 |
| Stochastic Oscillator | 57.97 | 0.17 |
Price Performance
Historical ComparisonAbout LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.